Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
The European Journal of Health Economics
Erschienen in:

20.12.2024 | Editorial

Obesity epidemic in European countries: from an unaddressed risk factor to a medicalized disease?

verfasst von: Livio Garattini, Giovanni Fattore

Erschienen in: The European Journal of Health Economics | Ausgabe 1/2025

Einloggen, um Zugang zu erhalten

Auszug

Since many decades obesity has become an international public health issue. Starting from the USA and then in Western European countries [1], nowadays obesity is a sort of pandemic which decreases quality of life and increases risk of illness almost everywhere in the world [2]. Defined by the WHO as the ‘new epidemic of the 21st century’, obesity can cause a wide range of diseases (e.g. diabetes, heart disease, kidney failure, osteoarthritis, stroke, depression) and a growth in mortality [3], eventually increasing health care costs and decreasing economic productivity [2, 4]. Moreover, the recent Covid-19 pandemic could have worsened the obesity epidemic, especially for children because of school closures and home confinement resulting in physical inactivity [5, 6]. …
Literatur
1.
Temple, N.J.: A proposed strategy against obesity: How government policy can counter the obesogenic environment. Nutrients. 15(13), 2910 (2023).
2.
Bray, G.A., Frühbeck, G., Ryan, D.H., Wilding, J.P.: Management of obesity. Lancet. 387(10031), 1947–1956 (2016).
3.
Song, J.E., Ko, H.J., Kim, A.S.: Comparison of the efficacy of anti-obesity medications in real-world practice. Drug. Des. Devel. Ther. 18, 845–858 (2024).
4.
Mello, M.M.: Obesity–personal choice or public health issue? Nat. Clin. Pract. Endocrinol. Metab. 4(1), 2–3 (2008).
5.
Borg, M., Cauchi, D., Gauci, C., Calleja, N.: Addressing childhood obesity through policy: A cross-sectional study in Malta. J. Prev. Med. Hyg. 64(3), E323–E336 (2023).
6.
Kumari, S., Shukla, S., Acharya, S.: Childhood obesity: Prevalence and prevention in modern society. Cureus. 14(11), e31640 (2022).
7.
Mehta, N.K.: Obesity as a main threat to future improvements in population health: Policy opportunities and challenges. Milbank Q. 101(S1), 460–477 (2023).
8.
Baker, P., Gill, T., Friel, S., Carey, G., Kay, A.: Generating political priority for regulatory interventions targeting obesity prevention: An Australian case study. Soc. Sci. Med. 177, 141–149 (2017).
9.
Klitzman, R., Greenberg, H.: Anti-obesity medications: Ethical, policy, and public health concerns. Hastings Cent. Rep. 54(3), 6–10 (2024).
10.
Abdi Beshir, S., Ahmed Elnour, A., Soorya, A., Parveen Mohamed, A., Sir Loon Goh, S., Hussain, N., Al Haddad, A.H.I., Hussain, F., Yousif Khidir, I., Abdelnassir, Z.: A narrative review of approved and emerging anti-obesity medications. Saudi Pharm. J. 31(10), 101757 (2023).
11.
Fry, C.L.: Ethical issues in obesity interventions for populations. NSW Public Health Bull. 23(5–6), 116–119 (2012).
12.
The Lancet Gastroenterology & Hepatology. Tackling obesity: Drugs are only part of the solution. Lancet Gastroenterol. Hepatol. 9(12), 1065 (2024).
13.
Callahan, D.: Obesity: Chasing an elusive epidemic. Hastings Cent. Rep. 43(1), 34–40 (2013).
14.
Prillaman M. Why BMI is flawed - and how to redefine obesity. Nature. 622(7982), 232–233 (2023).
15.
Collins, E., Beattie, A., Ramagopalan, S.V., Pearson-Stuttard, J.: First in class, best in class or a wild card: Who will dominate the anti-obesity medication market? J. Comp. Eff. Res. 13(7), e240044 (2024).
16.
Jeon, E., Lee, K.Y., Kim, K.K.: Approved anti-obesity medications in 2022 KSSO guidelines and the promise of phase 3 clinical trials: Anti-obesity drugs in the sky and on the horizon. J. Obes. Metab. Syndr. 32(2), 106–120 (2023).
17.
Hernandez, I., Wright, D.R., Guo, J., Shrank, W.H.: Medicare part D coverage of anti-obesity medications: A call for forward-looking policy reform. J. Gen. Intern. Med. 39(2), 306–308 (2024).
18.
Jhaveri, R. Our response to the obesity crisis reflects our bias as a society. Clin. Ther. 43(7), 1135–1137 (2021).
19.
Sahebkar, A., Gadde, K.M., Kroh, M., Eid. A.H., Jamialahmadi, T.: New generation anti-obesity pharmacotherapy: Companion or competitor to metabolic bariatric surgery? Drug. Discov. Today. 29(8), 104072 (2024).
20.
Wong, G., Garner, E.M., Takkouche, S., Spann, M.D., English, W.J., Albaugh, V.L., Srivastava, G.: Combination anti-obesity medications to effectively treat bariatric surgery weight regain at an academic obesity center. Obes. Sci. Pract. 9(3), 203–209 (2022).
21.
Ten Have, M.: Ethical aspects of obesity prevention. Best Pract. Res. Clin. Gastroenterol. 28(2), 303–314 (2014).
22.
Choi, Y.J., Choi, C.Y., Kim, C.U., Shin, S.: A nationwide pharmacovigilance investigation on trends and seriousness of adverse events induced by anti-obesity medication. J. Glob. Health. 13, 04095 (2023).
23.
Shaik Mohamed Sayed, U.F., Moshawih, S., Goh, H.P., Kifli, N., Gupta, G., Singh, S.K., Chellappan, D.K., Dua, K., Hermansyah, A., Ser, H.L., Ming, L.C., Goh, B.H.: Natural products as novel anti-obesity agents: Insights into mechanisms of action and potential for therapeutic management. Front. Pharmacol. 14, 1182937 (2023).
24.
Dehghani, F., Ali Ahmadi, M., Hefner, M., Kudchadkar, G., Najam, W., Nateqi, M., Siddik, M.A.B., Booe, H., Dhurandhar, N.V.: An algorithm for the use of anti-obesity medications. Nutr. Diabetes. 14(1), 20 (2024).
25.
Tulatz, K.: Obesity, political responsibility, and the politics of needs. Med. Health Care Philos. 22(2), 305–315 (2019).
26.
Azétsop, J., Joy, T.R.: Epistemological and ethical assessment of obesity bias in industrialized countries. Philos. Ethics Humanit. Med. 6, 16 (2011).
27.
Vargas, C.M., Stines, E.M., Granado, H.S.: Health-equity issues related to childhood obesity: A scoping review. J. Public Health Dent. 77(Suppl 1), S32–S42 (2017).
28.
Han, S.J., Lee, S.H.: Nontraditional risk factors for obesity in modern society. J. Obes. Metab. Syndr. 30(2), 93–103 (2021).
29.
Hagenaars, L.L., Schmidt, L.A., Groeniger, J.O., Bekker, M.P.M., Ter Ellen, F., de Leeuw, E., van Lenthe, F.J., Oude Hengel, K.M., Stronks, K.: Why we struggle to make progress in obesity prevention and how we might overcome policy inertia: Lessons from the complexity and political sciences. Obes. Rev. 25(5), e13705 (2024).
30.
Souza, L.M.S., Chaves, S.C.L., Santana, J.M., Pereira, M.: Public policy interventions for preventing and treating obesity: Scoping review. Nutr. Rev. 81(12), 1653–1664 (2023).
31.
Kass, N., Hecht, K., Paul, A., Birnbach, K.: Ethics and obesity prevention: Ethical considerations in 3 approaches to reducing consumption of sugar-sweetened beverages. Am. J. Public Health. 104(5), 787–795 (2014).
32.
Coggon, J., Adams, J.: ‘Let them choose not to eat cake…’: Public health ethics, effectiveness and equity in government obesity strategy. Future Healthc. J. 8(1), 49–52 (2021).
33.
Mytton, O., Boyland, E., Adams, J., et al.: The potential health impact of restricting less-healthy food and beverage advertising on UK television between 05.30 and 21.00 h: A modelling study. PLoS Med. 17, e1003212 (2020).
34.
Lobstein, T., Neveux, M., Landon, J.: Costs, equity and acceptability of three policies to prevent obesity: A narrative review to support policy development. Obes. Sci. Pract. 6(5), 562–583 (2020).
35.
Donovan, C.M., McNulty, B.: Living with obesity in Ireland: Determinants, policy and future perspectives. Proc. Nutr. Soc. 83(2), 82–94 (2024).
36.
Buchanan, D.: Ethical standards to guide the development of obesity policies and programs comment on “Ethical agreement and disagreement about obesity prevention policy in the United States”. Int. J. Health Policy Manag. 1(4), 313–315 (2013).
37.
Adams, J., Mytton, O., White, M., Monsivais, P.: Why are some population interventions for diet and obesity more equitable and effective than others? The role of individual agency. PLoS Med. 13(4), e1001990 (2016).
38.
Toorang, F., Amiri, P., Djazayery, A., Pouraram, H., Takian, A.: Worse becomes the worst: Obesity inequality, its determinants and policy options in Iran. Front. Public Health. 12, 1225260 (2024).
39.
Kersh, R., Stroup, D.F., Taylor, W.C.: Childhood obesity: A framework for policy approaches and ethical considerations. Prev. Chronic. Dis. 8(5), A93 (2011).
40.
Perryman, M.L.: Ethical family interventions for childhood obesity. Prev. Chronic. Dis. 8(5), A99 (2011).
41.
Hong, Y.H.: Pediatric obesity: Life cycle approach of pediatrician and society. Clin. Exp. Pediatr. 65(1), 29–30 (2022).
42.
Hillier-Brown, F.C., Bambra, C.L., Cairns, J.-M., et al.: A systematic review of the effectiveness of individual, community and societal level interventions at reducing socioeconomic inequalities in obesity amongst children. BMC Public Health. 11, 834 (2014).
Metadaten
Titel
Obesity epidemic in European countries: from an unaddressed risk factor to a medicalized disease?
verfasst von
Livio Garattini
Giovanni Fattore
Publikationsdatum
20.12.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
The European Journal of Health Economics / Ausgabe 1/2025
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-024-01752-5

Weitere Artikel der Ausgabe 1/2025

Healthcare resource utilisation and direct medical cost for individuals with 5q spinal muscular atrophy in Sweden

  • Open Access
  • Original Paper

Is there a link between health care utilisation and subjective well-being? An exploratory study among older Danes

  • Open Access
  • Original Paper

The impact of different perspectives on the cost-effectiveness of remote patient monitoring for patients with heart failure in different European countries

  • Open Access
  • Original Paper

Mapping functions for the PHQ-9 and GAD-7 to generate EQ-5D-3L for economic evaluation

  • Open Access
  • Original Paper

Letter to the Editor: Lazzaro responds to Kennedy et al.

  • Commentary

Do institutions matter for citizens’ health status? Empirical evidence from Italy

  • Open Access
  • Original Paper